TNFRSF9 and cancer: To demonstrate that our EV-based delivery approach is also applicable for the treatment of other cancer models where local administration is an option, we established a B16 F10 flank tumor model by injecting 0.5 M cells subcutaneously into mice and treated them with free CD137 agonistic antibody or EV-conjugated CD137 antibody via intratumoral administration.